Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>S&amp;P/ASX 200 gained 14% during 2021, higher than other developed markets in Asia-Pacific. Many healthcare stocks remained resilient to the resurgence of the COVID-19 pandemic and outperformed the broader market.</li>
<li>Despite the recent surge, Australia’s total infection and deaths numbers are lower than many comparable countries. Australian government has so far ruled out the possibility of lock down.</li>
<li>In this insight, we have discussed five high growth ideas, with attractive business model and strong growth opportunities. Despite Omicron, these stocks are expected to continue their strong performance.</li>
</ul>


S&amp;P/ASX 200 gained 14% during 2021, higher than other developed markets in Asia-Pacific. Many healthcare stocks remained resilient to the resurgence of the COVID-19 pandemic and outperformed the broader market.
Despite the recent surge, Australia’s total infection and deaths numbers are lower than many comparable countries. Australian government has so far ruled out the possibility of lock down.
In this insight, we have discussed five high growth ideas, with attractive business model and strong growth opportunities. Despite Omicron, these stocks are expected to continue their strong performance.


Australian Healthcare: High Growth Ideas for 2022

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Event-Driven

S&amp;P Dow Jones Indices will announce changes to the S&amp;P/ASX 100 and <a href="https://www.smartkarma.com/entities/s-p-asx-200" target="_blank" data-smartkarma-citation="entities:22901:1" rel="noopener">S&amp;P/ASX 200 (AS51 INDEX)</a> as part of the December index review on 3 December and the changes will be effective after the close of trading on 17 December.The review period for the rebalance ends on 19 November, so we are exactly two-thirds of the way through the review period.As of the close on 20 September, we see <a href="https://www.smartkarma.com/entities/pilbara-minerals-ltd" target="_blank" data-smartkarma-citation="entities:7460:1" rel="noopener">Pilbara Minerals (PLS AU)</a> as a potential inclusion to the S&amp;P/ASX100 and <a href="https://www.smartkarma.com/entities/link-administration-holdings-ltd" target="_blank" data-smartkarma-citation="entities:970:1" rel="noopener">Link Administration Holdings (LNK AU)</a> as a potential deletion.For the <a href="https://www.smartkarma.com/entities/s-p-asx-200" target="_blank" data-smartkarma-citation="entities:22901:1" rel="noopener">S&amp;P/ASX 200 (AS51 INDEX)</a>, potential inclusions are <a href="https://www.smartkarma.com/entities/imugene-ltd" target="_blank" data-smartkarma-citation="entities:20276:1" rel="noopener">Imugene Ltd (IMU AU)</a>, <a href="https://www.smartkarma.com/entities/paladin-energy-ltd" target="_blank" data-smartkarma-citation="entities:10117:1" rel="noopener">Paladin Energy (PDN AU)</a>, <a href="https://www.smartkarma.com/entities/amalgamated-holdings-ltd" target="_blank" data-smartkarma-citation="entities:20978:1" rel="noopener">Event Hospitality and Entertainment (EVT AU)</a>, <a href="https://www.smartkarma.com/entities/liontown-resources-ltd" target="_blank" data-smartkarma-citation="entities:20488:1" rel="noopener">Liontown Resources (LTR AU)</a> and <a href="https://www.smartkarma.com/entities/arena-reit" target="_blank" data-smartkarma-citation="entities:12209:1" rel="noopener">Arena Reit (ARF AU)</a>, while potential deletions are <a href="https://www.smartkarma.com/entities/kogan-com-ltd" target="_blank" data-smartkarma-citation="entities:23575:1" rel="noopener">Kogan.com (KGN AU)</a>, <a href="https://www.smartkarma.com/entities/redbubble-ltd" target="_blank" data-smartkarma-citation="entities:24321:1" rel="noopener">Redbubble Ltd (RBL AU)</a>, <a href="https://www.smartkarma.com/entities/monadelphous-group-ltd" target="_blank" data-smartkarma-citation="entities:553:1" rel="noopener">Monadelphous (MND AU)</a>, <a href="https://www.smartkarma.com/entities/omni-bridgeway-ltd" target="_blank" data-smartkarma-citation="entities:8840:1" rel="noopener">Imf Bentham Ltd (OBL AU)</a> and <a href="https://www.smartkarma.com/entities/spark-new-zealand-ltd-3dcc706a-f086-4dd4-882b-2a42a36ccf8d" target="_blank" data-smartkarma-citation="entities:26915:1" rel="noopener">Spark New Zealand (SPK AU)</a>.With multiple M&amp;A deal pending, including <a href="https://www.smartkarma.com/entities/afterpay-limited" target="_blank" data-smartkarma-citation="entities:26940:1" rel="noopener">Afterpay Touch (APT AU)</a>, <a href="https://www.smartkarma.com/entities/sydney-airport" target="_blank" data-smartkarma-citation="entities:19063:1" rel="noopener">Sydney Airport (SYD AU)</a>, <a href="https://www.smartkarma.com/entities/ausnet-services" target="_blank" data-smartkarma-citation="entities:10293:1" rel="noopener">Ausnet Services (AST AU)</a>, <a href="https://www.smartkarma.com/entities/oil-search-ltd" target="_blank" data-smartkarma-citation="entities:773:1" rel="noopener">Oil Search Ltd (OSH AU)</a> and <a href="https://www.smartkarma.com/entities/spark-infrastructure-group" target="_blank" data-smartkarma-citation="entities:595:1" rel="noopener">Spark Infrastructure (SKI AU)</a>, there could be more additions to the index if deals are completed or highly likely to be completed by end November.Short interest on most potential inclusions is quite low, while the short interest on many potential exclusions is quite high.

S&amp;P Dow Jones Indices will announce changes to the S&amp;P/ASX 100 and S&amp;P/ASX 200 (AS51 INDEX) as part of the December index review on 3 December and the changes will be effective after the close of trading on 17 December.The review period for the rebalance ends on 19 November, so we are exactly two-thirds of the way through the review period.As of the close on 20 September, we see Pilbara Minerals (PLS AU) as a potential inclusion to the S&amp;P/ASX100 and Link Administration Holdings (LNK AU) as a potential deletion.For the S&amp;P/ASX 200 (AS51 INDEX), potential inclusions are Imugene Ltd (IMU AU), Paladin Energy (PDN AU), Event Hospitality and Entertainment (EVT AU), Liontown Resources (LTR AU) and Arena Reit (ARF AU), while potential deletions are Kogan.com (KGN AU), Redbubble Ltd (RBL AU), Monadelphous (MND AU), Imf Bentham Ltd (OBL AU) and Spark New Zealand (SPK AU).With multiple M&amp;A deal pending, including Afterpay Touch (APT AU), Sydney Airport (SYD AU), Ausnet Services (AST AU), Oil Search Ltd (OSH AU) and Spark Infrastructure (SKI AU), there could be more additions to the index if deals are completed or highly likely to be completed by end November.Short interest on most potential inclusions is quite low, while the short interest on many potential exclusions is quite high.

ASX100/​200 Index Rebalance Preview: Potential December Changes With Large Impact

Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Equity Bottom-Up

Telix announced on 2 November 2020 that it has entered into a licensing agreement with China Grand Pharmaceutical (CGP) for the greater Chinese rights to its diagnostic and therapeutic products. The deal includes up to US$225m in potential cash payments, including a US$25m non-refundable upfront advance, as well as royalties on therapeutic products sales and a comarketing agreement for the diagnostic products. Additionally, CGP will make a US$25m equity investment in Telix.

Telix announced on 2 November 2020 that it has entered into a licensing agreement with China Grand Pharmaceutical (CGP) for the greater Chinese rights to its diagnostic and therapeutic products. The deal includes up to US$225m in potential cash payments, including a US$25m non-refundable upfront advance, as well as royalties on therapeutic products sales and a comarketing agreement for the diagnostic products. Additionally, CGP will make a US$25m equity investment in Telix.

Telix Pharmaceuticals - Telix signs a big China deal

On 24 September 2020 Telix announced it had submitted its NDA to the FDA for approval of TLX591-CDx, its positron emission tomography (PET) imaging agent targeting prostate-specific membrane antigen (PSMA). The agency has a statutory 12 months to complete its assessment (two to accept the application and 10 to review). TLX591-CDx would be the company’s first approved product and it is in preparations to be ready to launch the product in 2021, which includes establishing distribution and supply-chain relationships.

On 24 September 2020 Telix announced it had submitted its NDA to the FDA for approval of TLX591-CDx, its positron emission tomography (PET) imaging agent targeting prostate-specific membrane antigen (PSMA). The agency has a statutory 12 months to complete its assessment (two to accept the application and 10 to review). TLX591-CDx would be the company’s first approved product and it is in preparations to be ready to launch the product in 2021, which includes establishing distribution and supply-chain relationships.  


Telix Pharmaceuticals - TLX591-CDx NDA submitted

For the first time, Telix provided a profile of its deep pipeline outside its lead asset on its H120 earnings call. It presented the details of four assets derived from its existing pipeline, the majority of which are expected to be tested in the clinic before the end of the year. This provides a roadmap for the company beyond the upcoming potential approval for TLX591-CDx and completion of pivotal studies for TLX250-CDx.

For the first time, Telix provided a profile of its deep pipeline outside its lead asset on its H120 earnings call. It presented the details of four assets derived from its existing pipeline, the majority of which are expected to be tested in the clinic before the end of the year. This provides a roadmap for the company beyond the upcoming potential approval for TLX591-CDx and completion of pivotal studies for TLX250-CDx. 

Telix Pharmaceuticals - A look at future directions

Australia

Telix Pharmaceuticals Limited operates as a biotechnology company. The Company develops and commercializes molecularly-targeted radiation therapy for the treatment of prostate, renal, and brain cancer. Telix Pharmaceuticals serves patients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Telix Pharmaceuticals (TLX AU)

Australian Healthcare: High Growth Ideas for 2022

Australian equity market is expected to continue its superior performance in 2022. This insight has highlighted five high growth healthcare ideas,...

Tina Banerjee

ASX100/200 Index Rebalance Preview: Potential December Changes With Large Impact

There could be 1 change to the ASX100 and 5 changes to the ASX200 at the December rebalance. With a long M&A pipeline, there could be additional...

Brian Freitas

Telix Pharmaceuticals - Telix signs a big China deal

Telix announced on 2 November 2020 that it has entered into a licensing agreement with China Grand Pharmaceutical (CGP) for the greater Chinese...

Edison Investment Research

Telix Pharmaceuticals - TLX591-CDx NDA submitted

On 24 September 2020 Telix announced it had submitted its NDA to the FDA for approval of TLX591-CDx, its positron emission tomography (PET) imaging...

Edison Investment Research

Telix Pharmaceuticals - A look at future directions

For the first time, Telix provided a profile of its deep pipeline outside its lead asset on its H120 earnings call. It presented the details of...

Edison Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Australian Healthcare: High Growth Ideas for 2022

Australian equity market is expected to continue its superior performance in 2022. This insight has highlighted five high growth healthcare ideas,...

Tina Banerjee

ASX100/​200 Index Rebalance Preview: Potential December Changes With Large Impact

There could be 1 change to the ASX100 and 5 changes to the ASX200 at the December rebalance. With a long M&A pipeline, there could be additional...

Brian Freitas

Telix Pharmaceuticals - Telix signs a big China deal

Telix announced on 2 November 2020 that it has entered into a licensing agreement with China Grand Pharmaceutical (CGP) for the greater Chinese...

Edison Investment Research

Telix Pharmaceuticals - TLX591-CDx NDA submitted

On 24 September 2020 Telix announced it had submitted its NDA to the FDA for approval of TLX591-CDx, its positron emission tomography (PET) imaging...

Edison Investment Research

Telix Pharmaceuticals - A look at future directions

For the first time, Telix provided a profile of its deep pipeline outside its lead asset on its H120 earnings call. It presented the details of...

Edison Investment Research

ASX100/200 Index Rebalance Preview: Potential December Changes With Large Impact